Clinical Trials Browser

INDUSTRY × Interventional × ALT-803 × Clear all

NCT06745908 2026-05-05

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06765902 2026-05-05

Immunotherapy Before and After Surgery

Phase 2 Withdrawn

Prostatic Neoplasms

NCT06765954 2026-05-05

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

Phase 2 Withdrawn

Prostatic Neoplasms

NCT07488884 2026-04-29

ResQ108B-PANC

Phase 1 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT02138734 2026-03-31

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Phase 1/2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT07477366 2026-03-17

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Phase 2 Not yet recruiting

Lymphoma, B-Cell

NCT06061809 2026-02-12

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Phase 2 Recruiting

Glioblastoma

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04390399 2025-12-15

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04898543 2025-12-11

QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT06710288 2025-10-20

A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Phase 2 Recruiting

Platinum-resistant Ovarian Cancer

NCT03022825 2025-10-16

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Phase 2/3 Active not recruiting

190 enrolled 1 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06829823 2025-10-16

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT03169764 2025-02-24

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Squamous Cell Carcinoma of Head and Neck

NCT03169790 2025-02-24

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Phase 1/2 Withdrawn

Lymphoma, Non-Hodgkin

NCT03167164 2025-02-21

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Phase 1/2 Withdrawn

Carcinoma, Merkel Cell

NCT03167177 2025-02-21

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Melanoma

NCT03169738 2025-02-21

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Phase 1/2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03169777 2025-02-21

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Phase 1/2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT03175666 2025-02-21

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Phase 1/2 Withdrawn

Triple Negative Breast Neoplasms

NCT03197571 2025-02-21

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1/2 Withdrawn

Carcinoma, Transitional Cell

NCT03197584 2025-02-21

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Phase 1/2 Withdrawn

Ovarian Neoplasms

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT03563144 2025-02-21

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03574649 2025-02-21

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03647423 2025-02-21

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

Phase 1/2 Withdrawn

Chordoma

NCT01946789 2025-01-22

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors

Phase 1 Completed

26 enrolled 22 charts

Melanoma, Neoplasm Metastasis, Neoplasms

NCT03329248 2024-12-12

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Phase 1/2 Terminated

6 enrolled 15 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03563157 2024-12-11

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Phase 1/2 Terminated

2 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT02099539 2024-09-26

QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Terminated

19 enrolled 22 charts

Multiple Myeloma, Neoplasms, Recurrence

NCT03586869 2024-08-27

QUILT-3.080: NANT Pancreatic Cancer Vaccine

Phase 1/2 Terminated

3 enrolled 13 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03387085 2024-08-09

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Phase 1/2 Terminated

9 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT03853317 2024-08-09

QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

Phase 2 Terminated

9 enrolled 13 charts

Carcinoma, Merkel Cell

NCT03127098 2024-08-06

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

Phase 1/2 Terminated

3 enrolled 6 charts

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Thyroid Neoplasms

NCT03387111 2024-08-05

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Phase 1/2 Terminated

4 enrolled 14 charts

Carcinoma, Squamous Cell

NCT02384954 2024-07-03

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Phase 1/2 Terminated

43 enrolled 15 charts

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT04927884 2024-06-12

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Phase 1/2 Terminated

3 enrolled 9 charts

Advanced Triple Negative Breast Cancer

NCT03136406 2024-06-11

QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Phase 1/2 Terminated

3 enrolled 9 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03387098 2024-05-22

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Phase 1/2 Terminated

4 enrolled 9 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02465957 2024-05-02

QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)

Phase 2 Terminated

7 enrolled 11 charts

Carcinoma, Merkel Cell

NCT02559674 2020-01-27

QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel

Phase 1 Completed

Neoplasm Metastasis, Neoplasms